Skip to main content
Premium Trial:

Request an Annual Quote

Knobloch Sizes Down for Bigger Challenge

Premium

His new environment is a challenge, but Christian Knobloch, new vice president of business development at EuroProteome, is enjoying the change of scenery. Not only does he get to enjoy the up-and-coming area of Hennigsdorf near Berlin, but he also gets to move from a 1,000-person company to a faster-paced one where the head count is about 25.

EuroProteome uses mass spec and other proteomics technologies as well as bioinformatics tools to design diagnostics and therapeutics for epithelial cancers. Knobloch’s role is to seek out more business opportunities for what the company’s been doing.

He left his former job at Knoll, the pharmaceutical arm of BASF, late last year to join the venture-financed startup at the beginning of this year. Among his plans for EuroProteome: “to increase [the staff] to about 50 to 60,” he says. An IPO may also be in the offing, but there are no set plans for it. “Like with every startup, an IPO is the mid- and long-term goal.”

The startup atmosphere is agreeing with Knobloch. He explains that he likes the idea of achieving success not just by continuing to sell an old product but by creating a whole new business.

Though he has a background in oncology and immunology, it’s actually the business that’s most intriguing to Knobloch. “It’s on the edge between science and commerce — that’s an area I just find very interesting in general.” And unlike larger organizations where he’d be more narrowly focused, “the scope of responsibility I have here is truly a global one. I can work internationally,” he says.

— Meredith Salisbury

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.